This is a preview of subscription content, log in via an institution to check access.
Reference
Du X, et al. Clinical Benefits and Cost-Effectiveness of Moxifloxacin as Initial Treatment for Community-Acquired Pneumonia: A Meta-Analysis and Economic Evaluation. Clinical Therapeutics : Apr 2021. Available from: URL: http://doi.org/10.1016/j.clinthera.2021.03.006
Rights and permissions
About this article
Cite this article
Moxifloxacin in community-acquired pneumonia: better outcomes, lower cost in China. PharmacoEcon Outcomes News 876, 21 (2021). https://doi.org/10.1007/s40274-021-7635-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7635-x